Biotech entity
All 2 tracked stories fall under one category: pharma. Profound Medical is most often covered alongside Atea Pharmaceuticals, which appears in 1 of these 2 stories. At 5, the average consequence score sits below the same-window beat average of 5.9.
Last mentioned: Mar 6, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: pharma. Profound Medical is most often covered alongside Atea Pharmaceuticals, which appears in 1 of these 2 stories. At 5, the average consequence score sits below the same-window beat average of 5.9. Each story carries 3.5 original sources on average, compared with 3.2 for the broader beat in this window. This profile follows 2 Biotech stories mentioning Profound Medical across the period from March 5, 2026 to March 6, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 31 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Profound Medical. Shared-story counts are live from our verified record — not editorial picks.
Kura Oncology and Profound Medical reported fourth-quarter 2025 results, highlighting a pivotal shift toward commercial execution in precision oncology and medical technology. While both companies faced revenue headwinds, Kura's launch of KOMZIFTI and Profound's surprise earnings beat signal a maturing landscape for specialized therapies.
Atea Pharmaceuticals and Profound Medical headlined a busy earnings day for the biotech sector, revealing critical updates on antiviral pipelines and therapeutic device adoption. As companies report full-year 2025 results, the focus remains on cash preservation and the transition from R&D to commercial execution.
Profound Medical is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
